MedTrace Logo

Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma

NCT00367185 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2006-08-22

No results posted yet for this study

Summary

In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been used since the 1960s and is regarded as the standard of care in elderly patients. We assess whether the addition of thalidomide to this combination or adapted high-dose chemotherapy, using a melphalan 100 mg/m2 -based regimen, would improve survival.

Conditions

Interventions

DRUG

Thalidomide

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Jean-Yves MARY · U717 INSERM universite Paris7, Hopital Saint-Louis, Paris, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31
Completion
2005-10-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00367185 on ClinicalTrials.gov